References
- Niemeyer C M, Gelber R D, Tarbell N J, Donnelly M, Clavell L A, Blattner S R, et al. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood 1991; 78: 2514–2519
- Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol 2003; 21: 1798–1809
- Pui C H, Evans W E. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166–178
- Pui C H, Sandlund J T, Pei D, Campana D, Rivera G K, Ribeiro R C, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104: 2690–2696
- Schrappe M, Reiter A, Ludwig W D, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood 2000; 95: 3310–3322
- Evans W E, Schell M J, Pui C H. MTX Clearance is more important for intermediate-risk ALL. J Clin Oncol 1990; 8: 1115–1119
- Pui C H, Relling M V, Evans W E. Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukemia. Best Prac Res Clin Haematol 2003; 15: 741–756
- Pui C H, Relling M V, Downing J R. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535–1548
- Kager L, Check M, Yang W, Zaza G, Cheng Q, Panetta J C, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005; 115: 110–117